IDENTIFICATION & CHARACTERISATION OF MOLECULAR DRIVERS OF THERAPEUTIC RESISTANCE
With
Professor Pieter Eichhorn
Group Leader, Curtin Medical Research Institute &
Dean of Research Infrastructure & Professor at Curtin University
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
He subsequently worked Dr. Jose Baselga at the Vall d’Hebron Institute of Oncology and Harvard Medical School contributing to studies on signalling networks, resistance mechanisms, and ubiquitin pathway regulation in cancer.
A major career highlight has been the identification and characterisation of molecular drivers of therapeutic resistance, including work on PI3K pathway biology and ubiquitin-regulated oncogenic signalling, published in high-impact journals and informing biomarker-driven therapeutic strategies.
At Curtin University, he has established and led a multidisciplinary translational research program focused on deubiquitinases, epithelial plasticity, and non-coding RNA biology in breast and melanoma. In parallel, he has provided strategic leadership as Dean of Research Infrastructure, overseeing major national and institutional infrastructure investments, NCRIS-aligned initiatives, and large-scale collaborative platforms that enhance research capability and clinical translation.
COLLABORATIONS
National University of Singapore, Walter and Eliza Hall Institute, Peter Mac, Vall d’Hebron, Helmholtz Munich, University of Manchester,
FUNDING
World Cancer Research Fund, Cancer Council Wa, Australia Center for RNA Therapy in Cancer
Source: Supplied
https://orcid.org/0000-0001-5840-943X
-
Neuroscience, neuropharmacology and exercise science
Dr Jacob Thorstensen is an early-career Assistant Professor in Neuroscience and Physiology in the Faculty of Health Sciences & Medicine at Bond University. He is also an honorary research fellow in The School of Biomedical Sciences at The University of Queensland. His work has unveiled several new neuroscientific mechanisms which have future applications for movement disorders.
-
Genetics of the choroid and impact on eye health
Dr Samantha Lee is a Senior Research Fellow at Lions Eye Institute and the University of Western Australia. Dr Lee obtained her PhD in 2017 and the Queensland University of Technology and has since been working on the genetics and environmental causes of various eye diseases, with a focus on glaucoma and myopia. She has published 57 full-length scientific papers and her work has been cited over 1,000 times. She serves on the Editorial Board for the journal BMC Ophthalmology and Scientific Reports, and on the Research Advisory Committee for the Ophthalmic Research Institute of Australia.
-
Anaemia guidelines updated after 50 years
Professor Sant-Rayn Pasricha is the Acting Deputy Director at the Walter Eliza Hall Institute of Medical Research in Melbourne, Australia. He is also a clinical haematologist at the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. From a young age, Prof Pasricha dreamed of becoming a doctor and found joy in learning about the human body and how to care for patients. After completing medical school, he developed a passion for working in low and middle-income countries, which led him to spend time working in East Timor, India, and Central Australia with First Nations communities.
